Preventive and/or therapeutic agent for diabetes

A technology for diabetes and glycogen, which is applied in pharmaceutical formulations, metabolic diseases, drug combinations, etc., can solve problems such as hyperactive energy metabolism and unclear mechanism of action

Inactive Publication Date: 2007-09-19
MITSUBISHI TANABE PHARMA CORP
View PDF11 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, its mechanism of action has not been clarified
[0010] In addition, there are no reports to date that insulin preparations, sulfonylureas, rapid-acting insulin secretion enhancers, biguanides, α-glucosidase inhibitors, or glitazones are currently used

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preventive and/or therapeutic agent for diabetes
  • Preventive and/or therapeutic agent for diabetes
  • Preventive and/or therapeutic agent for diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0087] experiment method

[0088] KKAy mice (male, Japanese CLEA, 5 weeks old, N=4-5) were used. The control group was fed normal food, and the cholemide group was fed normal food containing 2% cholemide (UAR company (Villemoison sur Orge, France)).

[0089] After 12 days, an oral glucose load test was carried out according to the usual method. Blood was collected before the glucose load, and then a glucose solution was orally administered at a ratio of 2 g / kg body weight, and blood glucose values ​​were measured 30, 60, 90, and 120 minutes later.

[0090] After 1 week of the experiment, the livers of the mice were taken out, and the gene expression levels (correlated mRNA levels) of the bile acid synthase cyp7α, the inhibitory nuclear receptor SHP, the glycogenesis enzymes PEPCK and G6Pase were analyzed by real-time quantitative PCR. Determination.

[0091]The primer sequences used for the real-time quantitative PCR reaction are respectively, the sequences of the sequence ...

Embodiment 2

[0106] experiment method

[0107] KKAy mice (male, Japanese CLEA, 5 weeks old, N=6) were used. GW-4064 (J. Med. Chem. 2000, Vol. 43 (16), pp. 2971-2974), which is an FXR agonist, was orally administered at a dose of 10 mg / kg for four days. On day 5, the mice were dissected and the livers were removed. The gene expressions of cyp7α, SHP and PEPCK in the liver were determined by quantitative PCR. In addition, the primer sequences used in the real-time quantitative PCR reaction are the same as those in Example 1.

[0108] result

[0109] (1) Gene expression of cyp7α and SHP in the liver

[0110] The results are shown in FIG. 6 . Compared with the control group, the gene expression level of cyp7α decreased in the GW-4064 group (FIG. 6-1), while the gene expression level of SHP increased (FIG. 6-2). This result indicates that GW-4064, which is an FXR agonist, negatively regulates the synthesis of bile acids in the liver due to the increase of FXR activity.

[0111] (2) Gene ...

Embodiment 3

[0115] experiment method

[0116] C57BL6 mice (male, Charles River Laboratories (l'Arbresle, France), 5 weeks old, N=4-5) were used. Guggulipid is a general drug used as a drug for treating hyperlipidemia. In the present invention, the drug sold by Syntrax Innovations is used.

[0117] The control group (HFD-Control) was fed a high-fat diet (35.9% fat, UAR company (Villemoison sur Orge, France)), the Mukul group (HFD-Mukul) was fed a diet containing 2.5% Mukul Kool-Myrrh high-fat diet, colemide group (HDF-Colemid) was fed a high-fat diet containing 2% colemide.

[0118] Insulin loading test was performed according to the usual method at the 8th week of administration. Blood was collected before insulin load, and insulin was injected intraperitoneally, and blood glucose levels were measured 30, 60, and 90 minutes later.

[0119] At the 9th week of administration, an oral glucose load test was performed according to the usual method. Blood was collected before the glucose lo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A preventive and/or therapeutic agent for diabetes, comprising a substance capable of inhibiting the activity of farnesoid X receptor as an active ingredient.

Description

technical field [0001] The present invention relates to novel preventive and / or therapeutic agents for diabetes. Background technique [0002] It is known that farnesoid X receptor (FXR) is a nuclear receptor with bile acid as a ligand, and this receptor is the rate-limiting enzyme for cholesterol 7α hydroxylase ( cyp7α) gene expression is negatively regulated (Non-Patent Document 1). As the mechanism of this regulation, it is known that the activation of FXR leads to increased expression of an inhibitory nuclear receptor small heterodimer partner (SHP), and that SHP inhibits the expression of cyp7α (non-patented Literature 2, 3). [0003] Agents that change the activity of FXR are considered to be effective for diseases in which cholesterol levels exhibit abnormally high or low values, and anion exchange resins known as cholesterol-lowering agents are known to act by adsorbing bile, which is an endogenous ligand of FXR acid to inhibit FXR activity, thereby increasing the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/00A61K31/787A61K31/785A61P3/10
Inventor 铃木一夫坂井薰石井伸一杉本佳奈美约翰·奥威尔斯渡边光博
Owner MITSUBISHI TANABE PHARMA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap